| 1 |
33102759 | Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma. | 2020 Oct |
1 |
| 2 |
30402928 | Monitoring serum proangiogenic cytokines from hepatocellular carcinoma patients treated with sorafenib. | 2019 Jun |
1 |
| 3 |
31330833 | ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib. | 2019 Jul 20 |
2 |
| 4 |
27266362 | Angiogenic Response following Radioembolization: Results from a Randomized Pilot Study of Yttrium-90 with or without Sorafenib. | 2016 Sep |
1 |
| 5 |
26420960 | Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there? | 2015 Sep 28 |
1 |
| 6 |
24374901 | Technical considerations in the development of circulating peptides as pharmacodynamic biomarkers for angiogenesis inhibitors. | 2014 Jun |
1 |
| 7 |
24045661 | Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma. | 2013 Oct 15 |
1 |
| 8 |
21233403 | Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth. | 2011 Mar 1 |
1 |